Zydus Lifesciences has informed that a press release dated March 23, 2024 titled ‘Zydus receives tentative approval from USFDA for Letermovir Tablets, 240 mg and 480 mg’ is enclosed.
The above information is a part of company’s filings submitted to BSE.